

Supplementary table 1. Further details on study design, and anaesthetic protocols.

Author (year), country	Patient demographics				Specified anaesthetic protocol	Anaesthetic agents	Elective or emergency procedure?	Anaesthetic outcome data		
	Population (n)	Females (n)	Males (n)	Subgroups				Depth of anaesthesia	Emergence	Awareness
Randomised trials										
Arya, et al. ⁵⁸ (2013), India	70	35	35	SP: n=35, 18♀ BIS: n=35, 17♀	Yes	Induction: propofol + fentanyl	Elective	+	--	--
Avidan, et al. ⁵⁷ (2011), USA	5713	2413	3300	BIS: n=2861, 1240♀ ETAG: n=2852, 1173♀	Yes	Maintenance: volatiles (isoflurane, desflurane or sevoflurane)	Elective	--	--	+
Avidan, et al. ⁵⁶ (2008), USA	1941	902	1039	BIS: n=967, 451♀ ETAG: n=974, 451♀	Yes	Maintenance: volatiles (isoflurane, desflurane or sevoflurane)	Elective	--	--	+
Celebioglu, et al. ⁵⁵ (2002), Turkey	59	20	39	Droperidol: n=30, 12♀ Sevoflurane: n=29, 8♀	Yes	Induction: diazepam, etomidate, fentanyl Maintenance on CPB: sevoflurane OR droperidol + fentanyl	Elective	--	--	+
Deogaonkar, et al. ⁵⁴ (2011), USA	107	46	61	A: n=30, 14♀ B: n=20, 13♀ C: n=28, 10♀ D: n=29, 9♀	Yes	Induction: thiopentone + opioid Maintenance: isoflurane/N ₂ O ± opioid	Elective	--	+	--
Gan, et al. ⁵³ (1999), USA	274	178	96	Control: n=34; 16♀ SP: n=124; 84♀ BIS: n=115; 78♀	Yes	Induction / maintenance: propofol, alfentanil Maintenance: propofol + 50% N ₂ O	Elective	--	+	--
Goto, et al. ⁵² (2002), Japan	48	24	24	Xenon 45%: n=4, 4♀ Xenon 50%: n=8, 4♀ Xenon 55%: n=8, 4♀ Xenon 60%: n=8, 4♀ Xenon 65%: n=8, 4♀ Xenon 70%: n=8, 4♀ Xenon 75%: n=4, 0♀	Yes	Induction / maintenance: xenon	Elective	+	--	--
Greif, et al. ⁵¹ (2002), USA ^b	20	10	10	Placebo: n=20, 10♀ Auricular acupuncture: n=20, 10♀	Yes	Induction: propofol Maintenance: Desflurane, 70% N ₂ O	Nil procedure	+	--	--
Hall, et al. ⁵⁰ (2002), USA ^b	22	10	12	N ₂ O: 22, 10♀ Sevoflurane: 22, 10♀	Yes	Sedation: sevoflurane OR N ₂ O	Nil procedure	--	--	+
Kato, et al. ⁴⁹ (1993), Japan	39	20	19	Sevoflurane: n=21, 11♀ Isoflurane: n=18, 9♀	Yes	Maintenance: isoflurane or sevoflurane	Elective	-	+	--
Khanduja, et al. ⁴⁸ (2014), India	60	48	12	Control: n=30, 24♀ Dexmedetomidine: n=30, 24♀	Yes	Induction: thiopentone ± dexmedetomidine Maintenance: isoflurane	Not specified	+	--	--

Kodaka, et al. ⁴⁷ (2005), Japan	78	40	38	Sevoflurane: n=38, 20♀ Propofol: n=40, 20♀	Yes	Induction: propofol or sevoflurane	Elective	+	--	--
Kreuer, et al. ⁴⁶ (2003), Germany	120	60	60	SP: n=40, 20♀ BIS: n=40, 20♀ Nacrotrend: n=40, 20♀	Yes	Induction / maintenance: propofol-remifentanil	Elective	--	+	--
Lallemant, et al. ⁴⁵ (2003), France	30	24	6	Etomidate 0.2mg/kg: n=10, 9♀ Etomidate 0.4mg/kg: n=10, 6♀ Etomidate 0.6mg/kg: n=10, 9♀	Yes	Induction: etomidate	Elective	--	--	+
Miller, et al. ⁴⁴ (1996), USA	90	62	28	Placebo: n=21, 16♀ Midazolam 15mcg/kg: n=24, 17♀ Midazolam 30mcg/kg: n=23, 13♀ Midazolam 45 mcg/kg: n=22, 16♀	Yes	Induction: midazolam, propofol, alfentanil Maintenance: propofol	Elective	--	--	+
Myles, et al. ³⁴ (2004) (multi-national)	2463	927	1536	BIS: n=1225, 471♀ SP: n=1238, 454♀	No	Variety of anaesthetic agents	Both	--	+	+
Schneider, et al. ⁴³ (2003), Germany	40	16	24	Group 1: n=10, 2♀ Group 2: n=10, 6♀ Group 3: n=10, 2♀ Group 4: n=10, 6♀	Yes	Induction/maintenance: Sevoflurane/low dose remifentanil Group 2: Sevoflurane/high dose remifentanil Group 3: Propofol/low dose remifentanil Group 4: Propofol/high dose remifentanil	Elective	--	--	+
Sun, et al. ⁴² (2008), China	360	180	180	Midazolam 0.02mg/kg: 180, 90♀ Midazolam 0.06mg/kg: 180, 90♀	Yes	Sedation: midazolam	Elective	+	--	--
Tercan, et al. ⁴¹ (2005), Turkey	160	80	80	Desflurane: n=80, 40♀ Sevoflurane: n=80, 40♀	Yes	Induction: propofol, fentanyl Maintenance: desflurane or sevoflurane + N ₂ O	Elective	--	+	--
Wang, et al. ⁴⁰ (2019), China	32	16	16	Esketamine: n=16, 8♀ Ketamine: n=16, 8♀	Yes	Sedation: ketamine	Not specified	--	+	--
Ward, et al. ³⁹ (2002), USA ^b	12	6	6	IDD-D: n=11, 6♀ Diprivan: n=12, 6♀	Yes	Induction / maintenance: propofol	Nil procedure	--	+	--

Xiong, et al. ³⁸ (2019), China	120	60	60	Placebo: n=30, 15♀ Dexmedetomidine ng/mL: n=30, 15♀ Dexmedetomidine ng/mL: n=30, 15♀ Dexmedetomidine 0.8ng/mL: n=30, 15♀	0.4 0.6	Yes	Induction: propofol, dexmedetomidine Maintenance: propofol	Not specified	+	--	--
Zhang, et al. ³⁷ (2011) (China)	5173	2208	2965	BIS: n=2919, 1237♂ SP: n=2309, 971♂		Yes	Induction / maintenance: propofol	Not specified	--	--	+
Other interventional trials											
Bajaj, et al. ⁷⁶ (2007), India	120	60	60	--		Yes	Induction: fentanyl, propofol, midazolam Maintenance: propofol, 50% N ₂ O	Elective	--	+	--
Bell, et al. ⁷⁵ (1987), UK	794	379	415	--		Yes	Sedation: midazolam	Not specified	+	--	--
Choi, et al. ⁷⁴ (2016), Korea	40	20	20	--		Yes	Induction: dexmedetomidine, propofol	Not specified	+	--	--
Heggy, et al. ⁷³ (2020), Egypt	200	90	110	--		Yes	Induction: propofol or thiopentone Maintenance: isoflurane or sevoflurane	Elective	--	--	+
Hoymork, et al. ⁷² (2005), Norway	60	30	30	--		Yes	Induction / maintenance: propofol	Not specified	--	+	--
Hoymork, et al. ⁷⁰ (2003) (Norway)	21	14	7	--		Yes	Induction / maintenance: propofol-remifentanil	Not specified	--	+	--
Hoymork, et al. ⁷¹ (2000), Norway	18	9	9	--		Yes	Induction / maintenance: propofol-remifentanil	Not specified	--	+	--
Im, et al. ⁶⁹ (2011), Korea	135	71	64	18-29 y: n=45, 22♀ 30-39 y: n=45, 23♀ 40-54 y: n=45, 25♀		Yes	Induction / maintenance: propofol-remifentanil	Elective	--	+	--
Kerssens, et al. ⁶⁸ (2003), Netherlands	56	25	31	--		Yes	Induction / maintenance: propofol	Elective	--	--	+
Kodaka, et al. ⁶⁷ (2006), Japan ^b	35	17	18			Yes	Induction / maintenance: propofol	Elective	+	--	--
Li, et al. ⁶⁶ (2021), China	390	333	57	Low sevoflurane: n=69, 27♂ High sevoflurane: n=78, 30♂		Yes	Induction/maintenance: sevoflurane, sufentanil	Elective	+	--	+
Messahel, et al. ⁶⁵ (2007), Saudi Arabia	2328	1239	1089	--		Yes	Induction: fentanyl, thiopentone	Not specified	--	--	+

							Maintenance: isoflurane or sevoflurane + N ₂ O					
Riphaus, et al. ⁷⁷ (2017), Germany	219	108	111	--	Yes		Sedation: propofol	Both	--	+	--	
Schneider, et al. ⁶⁴ (2002), Germany	20	6	14	--	Yes		Induction: alfentanil, propofol Maintenance: propofol	Elective	--	--	+	
Schultz, et al. ⁶³ (2008), Germany	20	10	10	--	Yes		Induction / maintenance: propofol-remifentanil	Not specified	+	--	--	
Wadhwa, et al. ⁶² (2003), USA	34	17	17	--	Yes		Maintenance: desflurane	Elective	+	--	--	
Yen, et al. ⁶¹ (2011), Taiwan	60	30	30	--	Yes		Sedation: midazolam, alfentanil	Elective	+	--	--	
Yeo, et al. ⁶⁰ (2017), Korea	97	49	48	--	Yes		Sedation: midazolam, ketamine	Not specified	+	--	--	
Yu, et al. ⁵⁹ (2017) (China)	1244	546	698	--	Yes		Maintenance: CIIA group: sevoflurane + propofol TIVA group: propofol	Not specified	--	--	+	
Prospective, observational studies												
Buchanan, et al. ⁹⁴ (2011), Australia	500	247	253	--	No		Induction: propofol or thiopentone Maintenance: isoflurane, desflurane or enflurane, +/- N ₂ O	Elective	--	+	--	
Eger, et al. ⁹ (2003), multi-national	4945	1929	3016	--	No		Maintenance: desflurane, ether, halothane, methoxyflurane, sevoflurane or xenon	Not specified	+	--	--	
Ekman, et al. ⁹³ (2004), Sweden	4945	1929	3016	--	No		Variety of anaesthetic agents	Not specified	--	--	+	
Errando, et al. ⁹² (2008), Spain	4001	2321	1680	--	No		Variety of anaesthetic agents	Both	--	--	+	
Goldmann, et al. ⁹¹ (1987), UK	30	7	23	--	No		Induction / maintenance: fentanyl, halothane, N ₂ O	Elective	--	--	+	
Haensch, et al. ⁹⁰ (2009) Germany	656	417	239	--	No		Induction / maintenance: propofol	Elective	+	+	--	
Hou, et al. ⁸⁹ (2019) (China)	5404	2673	2731	--	No		Variety of anaesthetic agents	Not specified	--	--	+	
Lennertz, et al. ¹⁷ (2022), multi-national	338	232	106	--	No		Variety of anaesthetic agents	Not specified	--	--	+	

Liu, et al. ⁸⁸ (1991), UK	1000	624	376	--	No	Variety of anaesthetic agents	Not specified	--	--	+
Myles, et al. ⁸⁷ (2001), Australia	463	222	241	--	No	Variety of anaesthetic agents	Elective	--	+	--
Nordstrom, et al. ⁸⁶ (1997), Sweden	1000	718	282	--	No	Induction / maintenance: propofol, alfentanil	Not specified	--	--	+
Ranta, et al. ⁸⁵ (1998), Finland	2612	2004	608	--	No	Variety of anaesthetic agents	Elective	--	--	+
Sanders, et al. ¹⁸ (2017), 2017, multi-national	260	124	136	--	No	Variety of anaesthetic agents	Not specified	--	--	+
Sandin, et al. ⁴ (2000), Sweden	11,785	7053	4732		No	Variety of anaesthetic agents	Both	--	--	+
Sebel, et al. ²⁰ (2004), USA	19,757	11,310	8447	--	No	Variety of anaesthetic agents	Elective	--	--	+
Singla, et al. ⁸⁴ (2017), India	896	604	292	--	No	Variety of anaesthetic agents	Elective	--	--	+
Stait, et al. ⁸³ (2008), Australia	200	118	82	--	No	Variety of anaesthetic agents	Elective	--	--	+
Tamire, et al. ⁸² (2019), Ethiopia	1065	773	292	--	No	Variety of anaesthetic agents	Both	--	--	+
Wang, et al. ⁸¹ (2011), China	32	16	16	--	No	Variety of anaesthetic agents	Not specified	--	--	+
Wennervirta, et al. ⁸⁰ (2002), Finland	3841	2950	891	--	No	Variety of anaesthetic agents	Elective	--	--	+
Wilson, et al. ⁷⁹ (1975), USA	490	318	172	--	No	Variety of anaesthetic agents	Elective	--	--	+
Xu, et al. ⁷⁸ (2009), China	11,101	6022	5079	--	No	Variety of anaesthetic agents	Elective	--	--	+

Abbreviations: BIS, Bispectral index; CIIA, combined intravenous and inhaled anaesthesia; CPB, cardiopulmonary bypass; dexmed, dexmedetomidine; ETAG, end-tidal anaesthetic gas concentration; RCT, randomised control trial; SP, standard practice; TIVA, total intravenous anaesthesia; UK, United Kingdom; USA, United States of America.

+ = related data present; -- = related data not present.

^a Nested with data reported in Buchanan et al. (2006) and Leslie et al. (2005) papers

^b Cross-over study or cross-over pairs within study

Supplementary table 2. Database Search Strategy m

DATABASE: Embase Classic+Embase <1947 to 2022 August 19>		
#	Query	Results from 22 Aug 2022
1	exp general anesthesia/	110,142
2	exp propofol/	64,336
3	barbiturates.mp. or exp barbituric acid derivative/	174,860
4	benzodiazepines.mp. or exp benzodiazepine derivative/	259,708
5	exp halothane/ or exp nitrous oxide/ or exp inhalation anesthesia/ or exp isoflurane/ or exp desflurane/ or exp sevoflurane/ or exp inhalation anesthetic agent/ or exp enflurane/	189,905
6	exp ketamine/	51,877
7	exp xenon/	9,048
8	Adrenergic alpha-Agonists.mp. or exp alpha adrenergic receptor stimulating agent/	467,662
9	exp intravenous anesthetic agent/ or exp intravenous anesthesia/	13,919
10	emergence.mp.	154,626
11	depth of anaesthesia.mp. or exp anesthesia level/	8,270
12	exp anesthetic recovery/	8,648
13	exp unconsciousness/ or loss of consciousness.mp.	97,551
14	exp awareness/ or exp intraoperative awareness/ or isolated forearm technique.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word]	116,416
15	4 or 8	693,513
16	1 and 15	14,227
17	2 or 3 or 5 or 6 or 7 or 9 or 16	432,138
18	10 or 11 or 12 or 13 or 14	380,165
19	17 and 18	20,214
DATABASE: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations, Daily and Versions <1946 to August 01, 2022>		
#	Query	Results from 2 Aug 2022
1	exp Anesthesia, General/	61,144
2	exp Propofol/	16,188
3	exp Barbiturates/	54,129
4	exp Benzodiazepines/	68,414
5	exp Anesthetics, Inhalation/	55,870
6	exp Xenon/	7,989
7	exp Nitrous Oxide/	15,241
8	exp Ketamine/	14,267
9	exp Adrenergic alpha-Agonists/	166,202

10	exp Anesthetics, Intravenous/	84,102
11	emergence.mp.	129,920
12	depth of anaesthesia.mp.	750
13	depth of anesthesia.mp.	1,347
14	eye opening.mp.	2,160
15	exp Orientation/	28,554
16	recovery.mp. or exp Anesthesia Recovery Period/	555,764
17	loss of consciousness.mp. or exp Unconsciousness/	48,954
18	exp Intraoperative Awareness/ or exp Awareness/	21,881
19	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10	413,282
20	11 or 14 or 15 or 16	711,669
21	12 or 13 or 17	50,946
22	18 or 20 or 21	779,498
23	19 and 22	22,949
24	limit 23 to humans	16,573

Supplementary table 3. Further individual study data on outcome measures

Reference	Awareness parameters	Outcomes	Related variables ^a			
			Age (y)	Drug dosage	Duration of anaesthesia/ (min)	of surgery
Awareness						
Avidan, et al. ⁵⁷ (2011)	Incidence of awareness with recall (modified Brice questionnaire)	• Confirmed (n) = 27 (F:M 12:15)	BIS: 60 ± 14.2 ETAC: 61 ± 14.4	Median age-adjusted MAC: 0.9	NR	
Avidan, et al. ⁵⁶ (2008)	Incidence of awareness with recall (modified Brice questionnaire)	• Confirmed (n) = 4 (F:M 1:3) • Possible (n) = 5 (F:M 2:3)	BIS: 59.5 ± 14.8 ETAG: 59.2 ± 14.6	Mean time-averaged ETAG: BIS: 0.8 ± 0.25 MAC ETAG: 0.8 ± 0.23 MAC	NR	
Celebioglu, et al. ⁵⁵ (2002)	Incidence of awareness with recall (modified Brice questionnaire)	• Confirmed (n) = 5 (F:M 3:2)	Droperidol: 54 ± 16 Sevoflurane: 51 ± 15	NR		Droperidol: 265 ± 50 Sevoflurane: 274 ± 69
Ekman, et al. ⁹³ (2004)	Incidence of awareness with recall (modified Brice questionnaire)	• Confirmed (n) = 2 (F:M 1:1)	SP: 49 ± 19 BIS: 50 ± 19	NR		SP: 114 ± 72 BIS: 121 ± 72
Errando, et al. ⁹² (2008)	Incidence of awareness with recall (modified Brice questionnaire)	• Confirmed (n) = 22 (F:M 18:4)	51 ± 18	NR		120 ± 51
Goldmann, et al. ⁹¹ (1987)	Incidence of awareness with recall (structured interview)	• Confirmed (n) = 7 (F:M 0:7)	55.6	NR		NR
Hall, et al. ⁵⁰ (2002)	Recall/recognition scores of audio/visual prompts displayed during anaesthetic	Scores 10-20% poorer in M (LR chi-square < 0.004)	29 ± 7	NR		NR
Heggy, et al. ⁷³ (2020)	Incidence of awareness with recall (modified Brice questionnaire)	• Confirmed (n) = 1 (F:M 0:1)	44	NR		NR
Hou, et al. ⁸⁹ (2019)	Incidence of awareness with recall (modified Brice questionnaire)	• Confirmed (n) = 23 (F:M 9:14)	52.6 ± 13.4	NR		Mean NR
Kerssens, et al. ⁶⁸ (2003)	Incidence of positive intra-operative response using IFT	• No gender specific data provided	37 ± 10	NR		Pre-surgical: 39 ± 11 Surgical: 45 ± 17
	Incidence of awareness with recall (structured interview)	• Confirmed (n) = 9 (F:M 5:4)				
Lallemand, et al. ⁴⁵ (2003)	Incidence of awareness with recall (structured interview)	• Confirmed (n) = 0	Group 1: 52 (38-68) Group 2: 51 (35-78) Group 3: age 47 (32-57)	Etomidate dose Group 1: 0.2mg/kg Group 2: 0.4mg/kg Group 3: 0.6mg/kg	NR	
Lennertz, et al. ¹⁷ (2022)	Incidence of positive intra-operative response using IFT	• Responders: 11% (37/232; F:M 31:6)	30 ± 6.3	NR		NR
	Incidence of awareness with recall (structured interview)	• Confirmed awareness (n) = 1 (F:M 1:0)				

		• Possible awareness (n) = 5 (F:M 3:2)			
Li, et al. ⁶⁶ (2021)	Incidence of awareness with recall (structured interview)	• Confirmed awareness (n) = 0	Low sevoflurane: 51.32 ± 1.1 High sevoflurane: 49.46 ± 1.11	NR	Low sevoflurane: 214.14 ± 9.2 High sevoflurane: 2185 ± 9.0
Liu, et al. ⁸⁸ (1991)	Incidence of awareness with recall (structured interview)	• Confirmed (n) = 2 (F:M 1:1)	NR	NR	NR
Messahel, et al. ⁶⁵ (2007)	Incidence of awareness with recall (structured interview)	• Confirmed (n) = 0	38.6 (14-104)	NR	NR
Miller, et al. ⁴⁴ (1996)	Incidence of awareness with recall (structured interview)	• Confirmed (n) = 6 (F:M 6:0)	Placebo: 34 ± 11 Group 2: 35 ± 9 Group 3: 35 ± 9 Group 4: age 38 ± 12	Propofol	Placebo: 37 ± 9 Group 2: 37 ± 12 Group 3: 40 ± 14 Group 4: 41 ± 15
Myles, et al. ³⁴ (2004)	Incidence of awareness with recall (modified Brice questionnaire)	• Confirmed (n) = 13 (F:M 6:7) • Possible (n) = 37 (F:M 18:19)	BIS: 58.1 ± 16.5 SP: 57.5 ± 16.9	NR	BIS: 192 (90-264) SP: 186 (78-270)
Nordstrom, et al. ⁸⁶ (1997)	Incidence of awareness with recall (structured interview)	• Confirmed (n) = 2 (F:M 2:0)	42 ± 15	NR	56 ± 45
Ranta, et al. ⁸⁵ (1998)	Incidence of awareness with recall (modified Brice questionnaire)	• Confirmed (n) = 10 (F:M 8:2) • Possible (n) = 9 (F:M 9:0)	NR	NR	NR
Sanders, et al. ¹⁸ (2017)	Incidence of positive intra-operative response using IFT Incidence of awareness with recall (modified Brice questionnaire)	• Responders: 4.6% (12/260; F:M 7:5) • Confirmed (n) = 0	29 ± 7	NR	NR
Sandin, et al. ⁴ (2000)	Incidence of awareness with recall (modified Brice questionnaire)	• Confirmed (n) = 19 (F:M 12:7)	48 ± 19	NR	99 ± 65
Schneider, et al. ⁴³ (2003)	Incidence of awareness with recall (modified Brice questionnaire)	• Confirmed (n) = 0	Group 1: 35 y (22-54) Group 2: 53 y (22-72) Group 3: 44 y (28-66) Group 4: 51 y (21-79)	NR	NR
Schneider, et al. ⁶⁷	Incidence of positive intra-operative response using IFT	• Responders: 40% (8/20; F:M 3:5)	Responders: 40 ± 15 Non-responders: 45 ± 17	NR	NR
Sebel, et al. ²⁰ (2004)	Incidence of awareness with recall (modified Brice questionnaire)	• Confirmed (n) = 25 (F:M 16:9) • Possible (n) = 46 (F:M 27:19)	Responders: 52 ± 15 Possible responders: 48 ± 14 Non-responders: 48 ± 14	NR	NR
Singla, et al. ⁸⁴ (2017)	Incidence of awareness with recall (modified Brice questionnaire)	• Confirmed (n) = 3 (F:M 2:1)	Mean NR	NR	NR

	questionnaire)	2:1) • Possible (n) = 4 (F:M 3:1)	<30 y 25.89% 30-44 y 32.48% 45-59 y 25.78% >60 y 15.85%		
Stait, et al. ⁸³ (2008)	Incidence of awareness with recall (modified Brice questionnaire)	• Confirmed (n) = 8 (F:M 6:2)	58 ± 14	NR	NR
Tamire, et al. ⁸² (2019)	Incidence of awareness with recall (modified Brice questionnaire)	No significant difference	39.39 ± 18.8	NR	NR
Wang, et al. ⁸¹ (2011)	Incidence of awareness with recall (modified Brice questionnaire)	• Confirmed (n) = 21 (F:M 13:8) • Possible (n) = 205 (F:M 118:87)	45 ± 14	NR	No awareness: 148 ± 71 Possible/confirmed awareness: 157 ± 82
Wennervirta, et al. ⁸⁰ (2002)	Incidence of awareness with recall (modified Brice questionnaire)	• Confirmed (n) = 4 (F:M 4:0) • Possible (n) = 7 (F:M 7:0)	Outpatient: 37 ± 6 Inpatient: 46 ± 13	NR	NR
Wilson, et al. ⁷⁹ (1975)	Incidence of awareness with recall (modified Brice questionnaire)	• Confirmed (n) = 4 (F:M 4:0)	44.4 (15-38)	NR	F: 98.9 (10-300) M: 88.3 (20-310)
Xu, et al. ⁷⁸ (2009)	Incidence of awareness with recall (modified Brice questionnaire)	• Confirmed (n) = 46 (F:M 31:15)	49 ± 16	NR	<1 h (n) = 1046 1-2h (n) = 3778 >2h (n) = 6089
Yu, et al. ⁵⁹ (2017)	Incidence of awareness with recall (modified Brice questionnaire)	• Confirmed (n) = 14 (F:M 7:7)	53.67 ± 11.67	NR	96.69 ± 36.68
Zhang, et al. ³⁷ (2011)	Incidence of awareness with recall (modified Brice questionnaire)	Awareness with recall (n) • Confirmed BIS group = 4 (F:M 3:1) • Confirmed SP group = 15 (F:M 8:7)	BIS group: 46.95 ± 14.89 SP group: 46.06 ± 14.59	NR	<1 h (n) = 867 1-2h (n) = 2147 >2h (n) = 1894

Emergence from Anaesthesia

Bajaj, et al. ⁷⁶ (2007)	Time to eye opening (min)	• 6.87 ± 2.54 vs 8.78 ± 2.66 (p < 0.001)	F: 41.05 ± 13.18 M: 40.93 ± 13.84	Mean propofol (mg)	F: 72.12 ± 9.82 M: 73.37 ± 10.3
	Time to response to verbal command (min)	• 7.53 ± 2.05 vs 9.61 ± 2.14 (p < 0.001)		F: 721.45 ± 119.47	
	Time to extubation (min)	• 8.40 ± 1.60 vs 10.79 ± 1.70 (p < 0.001)		M: 737.63 ± 110.20	
Buchanan, et al. ⁹⁴ (2011)	Time to eye opening (min)	• 5.3 ± 3.5 vs 7.7 ± 4.0 (p < 0.0005)	F: 39.5 (17-75) M: 39.5 (18-70)	Mean ETAC (%)	F: 70.8 ± 42.5 M: 65 ± 43.5
	Time to obeying commands (min)	• 6.8 ± 7.3 vs 8.3 ± 5.1 (p = 0.01)		Desflurane: F, 4.16 ± 0.46; M, 4.53 ± 0.82	
	Duration of PACU stay (min)	• 38.8 ± 16.1 vs 33.7 ± 11.8 (p < 0.001)		Sevoflurane: F, 1.43 ± 0.66; M, 1.43 ± 0.64 Isoflurane: F, 0.70 ± 0.33; M, 0.73 ± 0.29	

				Enflurane: F, 0.77 ± 15; M, NA	
Deogaonkar, et al. ⁵⁴ (2011)	% 'awake' by 30mins post-op	• 83% vs 57% (p = 0.002)	Group A: 53 ± 16 Group B: 58 ± 15 Group C: 52 ± 15 Group D: 54 ± 16	NR	Group A: 300 (228-366) Group B: 276 (222-600) Group C: 354 (294-390) Group D: 306 (246-420)
Gan, et al. ⁵³ (1999)	Time to eye opening	• 7.0 ± 5.2 vs 11.2 ± 8.6 (p <0.05)	F: 40 ± 13 M: 41 ± 15	Propofol dose (mg/kg/min) F: 0.13 ± 0.3 M: 0.13 ± 0.3	F: 120 ± 63.6 M: 108 ± 46.2
	Time to response to verbal command (min)	• 8.1 ± 6.2 vs 11.7 ± 8.6 (p <0.05)			
Haensch, et al. ⁹⁰ (2009)	Time to extubation (min)	• 10.59 ± 4.90 vs 12.20 ± 5.16 (p <0.0001)	F: 53.4 ± 14.8 M: 50.5 ± 16.2	NR	F: 98.3 ± 43.5 M: 103.7 ± 47.1
Hoymork, et al. ⁷² (2005)	Time to response to verbal command (min)	• 5.6 ± 2.4 vs 18.2 ± 3.7 (p = 0.003)	F: 33.6 (22-47) M: 36.5 (22-60)	Propofol dose (mg/kg/min) F: 0.18 ± 0.03 M: 0.17 ± 0.03	F: 99 ± 36 M: 97 ± 43
Hoymork, et al. ⁷⁰ (2003)	Time to response to verbal command (min)	• 6.6 ± 3.5 vs 11.6 ± 3.2 (p <0.01)	F: 36.5 (23-53) M: 41.3 (25-50)	NR	67 (41-125)
Hoymork, et al. ⁷¹ (2000)	Time to response to verbal command (min)	• 12.6 ± 2.5 vs 19.0 ± 4.2 (p = 0.001)	44.8 ± 12.0	NR	NR
Im, et al. ⁶⁹ (2011)	Time to eye opening (min)	• 18-29 y: 9.9 ± 4.2 vs 12 ± 4.0 (NS) • 30-39 y: 9.93 ± 2.7 vs 11.8 ± 5.1 (NS) • 40-54 y: 9.4 ± 2.9 vs 12.9 ± 2.6 (p <0.05)	Age mean NR	Propofol dose (mg) 18-29 y: 588.8 ± 275.9 30-39 y: 609.2 ± 217.5 40-54 y: 567.8 ± 195.9	18-29 y: 75.1 ± 36.4 30-39 y: 77.7 ± 30.8 40-54 y: 71.9 ± 22.4
	Time to orientation (min)	• 18-29 y: 11.2 ± 4.2 vs 13.2 ± 4.1 (NS) • 30-39 y: 10.9 ± 3.1 vs 13.2 ± 5.2 (NS) • 40-54 y: 11.6 ± 3.7 vs 14.4 ± 2.9 (p <0.05)			
Katoh, et al. ⁴⁹ (1993)	Awakening concentration (%) of volatile	• Non-significant difference	Sevoflurane: 42.9 ± 15.3 Isoflurane: 41.9 ± 15.8	--	Sevoflurane: 145.1 ± 59.5 Isoflurane: 151.4 ± 40.3
Kreuer, et al. ⁴⁶ (2003)	Time to eye opening (min)	• SP: 6.9 ± 2.6 vs 11.7 ± 6.1 (p = 0.003)	SP: 46.1 ± 14.5 BIS: 43.8 ± 4.2	Propofol dose (mg/kg/h)	SP: 108.2 ± 44.2 BIS: 121.2 ± 40.9

		<ul style="list-style-type: none"> • BIS: 3.1 ± 2.0 vs 3.9 ± 3.6 (NS) • Narcotrend: 2.9 ± 1.8 vs 3.9 ± 2.4 (NS) 	Narcotrend: 44.8 ± 15.9	SP: 6.8 ± 1.2 BIS: 4.8 ± 1.0 Narcotrend: 4.5 ± 1.1	Narcotrend: 126.9 ± 67.7
	Time to extubation (min)	<ul style="list-style-type: none"> • SP: 7.4 ± 2.6 vs 12.0 ± 6.3 (p = 0.005) • BIS: 4.7 ± 3.6 vs 3.5 ± 2.0 (NS) • Narcotrend: 3.2 ± 2.2 vs 4.2 ± 2.2 (NS) 			
Myles, et al. ³⁴ (2004)	Time to eye opening ^e (min)	<ul style="list-style-type: none"> • 8 vs 10 (median time; p <0.001) • 12 ± 22.6 vs 18 ± 45.9 (p <0.05) 	BIS: 58.1 ± 16.5 SP: 57.5 ± 16.9	NR	F: 162 ± 120.6 M: 212.4 ± 129.6
	Time to extubation (for patients admitted to ICU) (h)	<ul style="list-style-type: none"> • 12 vs 10 (median time; p = 0.004) 			
	Duration of PACU stay ^f (min)	<ul style="list-style-type: none"> • 59 vs 70 (median time; p = 0.004) • 67.4 ± 49.1 vs 85.0 ± 56.8 (p <0.0005) 			
Myles, et al. ⁸⁷ (2001)	Time to eye opening (min)	<ul style="list-style-type: none"> • 11.3 (95% CI 10.4-12.32) vs 13.4 (95% CI 12.4 – 14.3) (p = 0.003) 	F: 42 ± 15 M: 42 ± 28	NR	F: 94 ± 62 M: 83 ± 52
	Time to obeying commands (min)	<ul style="list-style-type: none"> • 12.4 (95% CI 11.3 – 13.7) vs 15.3 (95% CI 14.1 – 16.4) (p = 0.02) 			
	Duration of PACU stay (min)	<ul style="list-style-type: none"> • 66 (95% CI 63 – 70) vs 64 (95% CI 60 – 67) (NS) 			
Riphaus, et al. ⁷⁷ (2017)	Time to eye opening (min)	<ul style="list-style-type: none"> • 7.3 ± 3.7 vs 8.4 ± 3.4 (p <0.01) 	F: 66.9 ± 16.0 M: 64.8 ± 15.1	Propofol dose (mg/kg)	F: 23.2 ± 12.3 M: 23.8 ± 13.9
	Time to orientation (min)	<ul style="list-style-type: none"> • 9.1 ± 3.9 vs 10.4 ± 3.7 (p <0.01) 		F: 3.98 ± 1.81 M: 3.72 ± 1.75	
Tercan, et al. ⁴¹ (2005)	Time to eye opening (min)	<ul style="list-style-type: none"> • Desflurane: 6.0 ± 1.3 vs 4.9 ± 0.9 (p <0.001) • Sevoflurane: 6.9 ± 1.3 vs 6.1 ± 0.9 (p = 0.001) 	Desflurane: F: 44.7 ± 7.6 M: 41.5 ± 7.5 Sevoflurane: F: 43.5 ± 8.0 M: 42.7 ± 10.3	NR	Desflurane: F: 118.9 ± 13.8 M: 116.4 ± 9.4 Sevoflurane: F: 121.6 ± 14.9 M: 116.2 ± 9.4
	Time to extubation (min)	<ul style="list-style-type: none"> • Desflurane: 3.96 ± 0.6 vs 2.7 ± 0.6 (p <0.001) • Sevoflurane: 4.6 ± 1.2 vs 3.97 ± 0.7 (p = 0.009) 			
	Time to orientation (min)	<ul style="list-style-type: none"> • Desflurane: 9.7 ± 1.8 vs 			

		9.3 ± 1.4 (NS)			
		• Sevoflurane: 9.6 ± 1.8 vs 9.5 ± 1.1 (NS)			
Wang, et al. ⁸¹ (2011)	Time to recovery (OAAS/S score >5) (min)	• Esketamine: 9.5 (4-15) vs 8.5 (5-13) (NS)	Esketamine: 32.0 ± 6.19	Esketamine: 0.5 mg/kg	NR
		• Racemate ketamine: 14.5 (8-17) vs 11.5 (5-26) (NS)	Ketamine: 40.0 ± 8.91	Ketamine: 1 mg/kg	
	Time to orientation (min)	• Esketamine: 11 (6-25) vs 11.5 (6-19) (NS)			
		• Racemate ketamine: 17.5 (13-21) vs 16 (6-29) (NS)			
Ward, et al. ³⁹ (2002)	Time to eye opening (sec)	• IDD-D: 931 ± 250 vs 1517 ± 427 (p <0.01)	IDD-D: 26 ± 8.7	Propofol dose (mg/kg): 8.5	30 ± 0
		• Diprivan: 777 ± 378 vs 1234 ± 352 (p <0.01)	Diprivan: 26 ± 8.7		
Depth of Anaesthesia					
Arya, et al. ⁵⁸ (2013)	Propofol dose for loss of response to verbal command (SP group) (mg/kg)	• 1.65 ± 0.44 vs 2.06 ± 0.45 (p = 0.0002)	SP: 34.2 ± 10.5 BIS: 32.7 ± 12.7	--	NR
	Propofol dose for sustained BIS value of 48 ± 2 (BIS group) (mg/kg)	• 1.75 ± 0.49 vs 1.83 ± 0.32 (NS)			
Bell, et al. ⁷⁵ (1987)	Midazolam dose to achieve sedation (drowsy but still able to cooperate) (mg)	• 6.4 vs 7.4 (NS)	57.5	--	NR
Choi, et al. ⁷⁴ (2016)	Propofol EC ₅₀ for successful insertion of LMA (mcg/mL)	• 3.82 ± 0.34 vs 5.46 ± 0.26 (p <0.01)	F: 35 ± 11 M: 35 ± 9	Propofol mean dose F: 2.77 ± 0.41 mg/kg M: 3.35 ± 0.81 mg/kg	NR
Eger, et al. ⁹ (2003)	MAC (%) for normalised-combined data ^b	• 1.013 ± 0.017 vs 1.005 ± 0.009 (NS)	NR	--	NR
Goto, et al. ⁵² (2002)	Xenon ET % for 1 MAC	• 51.1 (44.6-57.6) vs 69.3 (63-75.6)	F: 71 ± 5 M: 70 ± 3	--	NR
Greif, et al. ⁵¹ (2002)	ET % for 1 MAC	• Control: 5.5 ± 1.0 vs 4.6 ± 0.6 (p <0.05)	F: 26 ± 6 M: 28 ± 5	--	Control: 169 ± 40 Intervention: 171 ± 49
		• Intervention: 4.7 ± 0.6 vs 4.2 ± 0.6 (NS)			
Haensch, et al. ⁹⁰ (2009)	Propofol dose during steady state anaesthesia (D ₂ /E ₀ on EEG) ^c (mg/kg/ LBM/h)	• Control: 3.92 ± 0.324 vs 3.69 ± 0.230	F: 53.4 ± 14.8 M: 50.5 ± 16.2	--	F: 98.3 ± 43.5 M: 103.7 ± 47.1
		• Dexmedetomidine: 2.55 ± 0.184 vs 2.76 ± 0.467			
Khanduja, et al. ⁴⁸ (2014)	Mean thiopentone dose for induction (loss of eyelash reflex) with or without dexmedetomidine (mg/kg)	• Control: 3.92 ± 0.324 vs 3.68 ± 0.230	Control: 40.4 ± 11.1 Dexmedetomidine: 42.4 ± 12.1	--	NR
		• Dexmedetomidine: 2.55 ± 0.184 vs 2.76 ± 0.467			

Kodaka, et al. ⁶⁷ (2006)	Measured and predicted propofol P ₅₀ for LOC (mcg/mL)	<ul style="list-style-type: none"> • Predicted: 2.55 ± 0.11 vs 2.14 ± 0.10 (p <0.0001) • Measured: 2.30 ± 0.28 vs 2.37 ± 0.41 (NS) 	F: 40.1 ± 12.6 M: 36.4 ± 10.0	--	NR
Kodaka, et al. ⁴⁷ (2005)	P ₅₀ for LOC for propofol (mcg/mL) or sevoflurane (%)	<ul style="list-style-type: none"> • Sevoflurane: 0.92 ± 0.09 vs 0.83 ± 0.13 (NS) • Propofol: 2.7 ± 0.1 vs 2.9 ± 0.2 (p <0.05) 	Sevoflurane: 31 ± 6 29 ± 7 Propofol: F: 29 ± 7 M: 30 ± 7	--	NR
Li, et al. ⁶⁶ (2021)	Mean sevoflurane ET % for BIS 40-60	• 1.574 ± 0.232 vs 1.637 ± 0.266 (NS)	Low sevoflurane: 51.32 ± 1.1 High sevoflurane: 49.46 ± 1.11	--	Low sevoflurane: 214.14 ± 9.2 High sevoflurane: 2185 ± 9.0
Myles, et al. ³⁴ (2004)	BIS value during maintenance of anaesthesia	• 46.4 ± 6.6 vs 44.6 ± 7.1 (p = 0.005)	F: 46.4 ± 18 M: 56.5 ± 16	Age-adjusted MAC F: 1.26 ± 0.3 M: 1.31 ± 0.3	F: 34.2 ± 7.8 M: 34.8 ± 7.8
Schultz, et al. ⁶³ (2008)	Time to intra-operative EEG suppression (min)	• 4.78 ± 1.07 vs 4.72 ± 1.20 (NS)	F: 49.7 ± 17.7 M: 42.8 ± 13.5	NR	NR
Sun, et al. ⁴² (2008)	OAA/S scores associated with midazolam dose (mg/kg)	60-79yr: • 0.02 mg/kg: 4.80 vs 4.30 • 0.06 mg/kg: 3.20 vs 2.80 40-59yr: • 0.02 mg/kg: 4.76 vs 4.36 • 0.06 mg/kg: 3.72 vs 3.36 20-39yr • 0.02 mg/kg: 4.76 vs 4.57 • 0.06 mg/kg: 4.37 vs 3.43	Mean NR	Midazolam: 0.02mg/kg or 0.06 mg/kg	NR
Wadhwa, et al. ⁶² (2003)	ET % for 1 MAC	• 6.2 ± 0.4 vs 6.0 ± 0.3 (NS)	F: 33 ± 9 M: 27 ± 8	--	F: 24 ± 7 ^d M: 23 ± 10 ^d
Xiong, et al. ³⁸ (2019)	Propofol EC ₅₀ for LOC (mcg/mL)	<ul style="list-style-type: none"> • Group 1: 2.17 vs 2.43 (p <0.05) • Group 2: 1.82 vs 1.99 (p <0.05) • Group 3: 1.56 vs 1.72 (p <0.05) • Group 4: 1.32 vs 1.50 (p <0.05) 	Group 1: F: 41.8 ± 6.2 M: 43.3 ± 6.2 Group 2: F: 44.3 ± 4.4 M: 41.1 ± 7.8 Group 3: F: 43.5 ± 4.6 M: 41.7 ± 7.7 Group 4: F: 42.5 ± 6.7 M: 40.1 ± 7.3	--	NR
Yen, et al. ⁶¹ (2011)	Mean midazolam (0.5mg/mL) + alfentanil (0.1mg/mL) for sedation (mL)	• 4.8 ± 0.8 vs 4.4 ± 0.7 (p <0.05)	F: 46.9 (30-65) M: 49.6 (34-64)	--	F: 11.5 ± 3.0 M: 11.2 ± 2.2
Yeo, et al. ⁶⁰ (2017)	Depth of sedation (BIS score) for midazolam 0.04mg/kg + ketamine 0.2mg/kg	• Non-significant difference	45.5 ± 11.8	Midazolam 0.04mg/kg and	NR

ketamine
0.2mg/kg

Abbreviations: BIS, Bispectral Index (processed EEG monitor); CI, confidence interval; EC₅₀, effect-site concentration for 50% patients; EEG, electroencephalography; ET, end-tidal; ETAG, end-tidal anaesthetic gas concentration; ICU, intensive care unit; IDD-D, propofol 2%; LMA, laryngeal mask airway; IFT, isolated forearm technique; LOC, loss of consciousness; ; LR, likelihood ratio; MAC, minimum alveolar concentration; NR, not reported; NS, non-significant; OAA/S, observer's assessment of alertness and sedation; P50, plasma concentration for 50% of patients; pEEG, processed electroencephalogram; PACU, post-anaesthesia care unit; SP, standard practice; TCI, target controlled infusion.

^a Reported in mean +/- SD or mean (range) unless otherwise indicated

^b Data reported in mean ± SEM

^c D2/E₀: stage of deep anaesthesia where the raw EEG is characterised by a substantial amount of delta (0.5-3.5Hz) waves

^d Time from induction to surgical incision/ET % measurement

^e Study population excludes those admitted to ICU post-operatively mechanically ventilated

^f Study population excludes those admitted directly to ICU post-operatively

Supplementary table 4. Summary Table of Different Models for Confirmed AAGA data.

Statistical Model	Effect Size				prediction	Heterogeneity	
	Odds Estimate	Ratio	95% CI	95% interval		P-value	τ^2
Peto	1.39		1.10 - 1.75	N/A		0.01	NA
Mantel-Haenszel	1.40		1.10 - 1.78	N/A		0.01	NA
DerSimonian-Laird*	1.35		1.13 - 1.60	1.13 - 1.60		0.00	0
Paule-Mandel*	1.35		1.13 - 1.60	1.13 - 1.60		0.00	0
Restricted Likelihood*	1.35	Maximum	1.13 - 1.60	1.13 - 1.60		0.00	0
Restricted Likelihood HKSJ	1.35	Maximum with modified	1.05 - 1.73	1.05-1.73		0.02	0
Restricted Likelihood without HKSJ	1.35	Maximum	1.06 - 1.71	1.06 - 1.71		0.02	0
Generalised Linear Mixed-Effects Model†,‡	1.39		1.09 - 1.76	1.09 - 1.76		0.02	0
Arcsine Difference							
Restricted Likelihood HKSJ	0.01	Maximum with modified	0.00 - 0.02	0.00 - 0.02		0.02	0

* Confidence interval calculated using HKSJ adjustment
† Confidence interval calculated using t-distribution
‡ Conditional model, approximate likelihood

Supplementary table 5. Summary Table of Different Models for Confirmed or Total AAGA data.

Statistical Model	Effect Size				Heterogeneity	
	Odds Estimate	Ratio	95% CI	95% interval	prediction	P-value τ^2
Peto	1.38		1.13 – 1.69	N/A		0.00 NA
Mantel-Haenszel	1.40		1.14 – 1.72	N/A		0.00 NA
DerSimonian-Laird*	1.35		1.14 – 1.59	1.14 – 1.59		0.00 0
Paule-Mandel*	1.35		1.14 – 1.59	1.14 – 1.59		0.00 0
Restricted Likelihood*	Maximum	1.35	1.14 – 1.59	1.14 – 1.59		0.00 0
Restricted Likelihood with HKSJ	Maximum modified	1.35	1.09 – 1.67	1.09 – 1.67		0.01 0
Restricted Likelihood without HKSJ	Maximum	1.35	1.09 – 1.66	1.09 – 1.66		0.01 0
Generalised Linear Mixed-Effects Model†,‡		1.38	1.13 – 1.70	1.13 – 1.70		0.00 0
Arcsine Difference						
Restricted Likelihood*	Maximum	0.01	0.00 – 0.02	-0.01 – 0.03		0.01 0

* Confidence interval calculated using HKSJ adjustment
† Confidence interval calculated using t-distribution
‡ Conditional model, approximate likelihood

Supplementary table 6. Sequential exclusion analysis for confirmed or possible AAGA data.

Authors, Year	Effect Size				Heterogeneity				
	Odds Ratio	p-value	95% Lower bound	CI	95% Upper bound	CI	Cochran's Q	p-value	I ² (%)
Avidan et al. (a; ETAG), 2008	1.39	0.01*	1.10		1.76		23.85	0.69	0
Avidan et al. (a; BIS), 2008	1.41	0.00*	1.11		1.78		21.44	0.81	0
Avidan et al. (b), 2011	1.42	0.01*	1.11		1.82		23.46	0.71	0
Ekman et al., 2004	1.39	0.01*	1.09		1.75		23.86	0.69	0
Errando et al., 2008	1.31	0.03*	1.03		1.68		21.38	0.81	0
Goldman et al., 1987	1.43	0.00*	1.13		1.81		19.95	0.87	0
Kerssens et al., 2003	1.38	0.01*	1.09		1.75		23.80	0.69	0
Lallemant et al. (0.2mg/kg), 2003	1.39	0.01*	1.10		1.75		23.87	0.74	0
Lallemant et al. (0.3mg/kg), 2003	1.39	0.01*	1.10		1.75		23.87	0.74	0
Lallemant et al. (0.4mg/kg), 2003	1.39	0.01*	1.10		1.75		23.87	0.74	0
Lennertz et al., 2022	1.38	0.01*	1.09		1.75		23.59	0.70	0
Liu et al., 1999	1.39	0.01*	1.10		1.77		23.52	0.71	0
Messahel et al., 2007	1.39	0.01*	1.10		1.75		23.87	0.74	0
Miller et al. (PLAC), 1996	1.37	0.01*	1.09		1.74		23.18	0.72	0
Miller et al. (M-15), 1996	1.38	0.01*	1.09		1.75		23.64	0.70	0
Miller et al. (M-30), 1996	1.39	0.01*	1.10		1.75		23.87	0.74	0
Miller et al. (M-45), 1996	1.38	0.01*	1.09		1.75		23.65	0.70	0
Myles et al. (BIS), 2004	1.38	0.01*	1.09		1.75		23.86	0.69	0
Myles et al. (RC), 2004	1.38	0.01*	1.09		1.76		23.86	0.69	0
Nordstrom et al., 1997	1.38	0.01*	1.09		1.74		23.40	0.71	0
Sanders et al., 2017	1.39	0.01*	1.10		1.75		23.87	0.74	0
Sandin et al., 2000	1.40	0.01*	1.10		1.79		23.69	0.70	0
Schneider et al. (Sevo, low remi), 2003	1.39	0.01*	1.10		1.75		23.87	0.74	0
Schneider et al. (Sevo, high remi), 2003	1.39	0.01*	1.10		1.75		23.87	0.74	0
Schneider et al. (Prop, low remi), 2003	1.39	0.01*	1.10		1.75		23.87	0.74	0
Schneider et al. (Prop, high remi), 2003	1.39	0.01*	1.10		1.75		23.87	0.74	0
Sebel et al., 2014	1.39	0.01*	1.09		1.78		23.86	0.69	0
Singla et al., 2017	1.39	0.01*	1.10		1.76		23.78	0.69	0
Wang et al., 2011	1.39	0.01*	1.09		1.77		23.87	0.69	0
Wennervirta et al., 2002	1.37	0.01*	1.08		1.74		23.18	0.72	0
Wilson et al., 1975	1.36	0.01*	1.08		1.73		22.49	0.76	0
Xu et al., 2009	1.33	0.03*	1.03		1.72		23.29	0.72	0
Yu et al., 2017	1.39	0.01*	1.09		1.77		23.85	0.69	0
Zhang et al. (BIS),	1.38	0.01*	1.09		1.75		23.71	0.70	0

2011							
Zhang et al. (RC), 2011	1.42	0.00*	1.12	1.81	22.93	0.74	0
Celebioglu et al., 2022	1.37	0.01*	1.08	1.73	22.96	0.73	0
Heggy et al., 2020	1.40	0.01*	1.10	1.77	22.72	0.75	0
Hou et al., 2019	1.49	0.00*	1.16	1.90	20.08	0.86	0
Li et al., 2021	1.39	0.01*	1.10	1.75	23.87	0.74	0
Ranta et al., 1998	1.39	0.01*	1.10	1.77	23.83	0.69	0
Stait et al., 2008	1.34	0.02*	1.05	1.70	20.53	0.84	0

* p < 0.05

Abbreviations: BIS, Bispectral index; CI, confidence interval; ETAG, end-tidal anaesthetic gas; E-0.2, etomidate 0.2 mg/kg; E-0.3, etomidate 0.3 mg/kg; E-0.4, etomidate 0.4 mg/kg; M-15, midazolam 15 mcg/kg; M-30, midazolam 30 mcg/kg; M-45, midazolam 45 mcg/kg; PLAC, placebo; Prop, propofol; remi, remifentanyl; Sevo, sevoflurane; SP, standard practice.

Supplementary table 7. Sequential exclusion analysis for confirmed or total AAGA data.

Authors, Year	Effect Size				Heterogeneity				
	Odds Ratio	p-value	95% Lower bound	CI	95% Upper bound	CI	Cochran's Q	p-value	I ² (%)
Avidan et al. (a; ETAG), 2008	1.38	0.00*	1.13		1.68		27.37	0.50	0
Avidan et al. (a; BIS), 2008	1.42	0.00*	1.16		1.73		24.00	0.68	0
Avidan et al. (b), 2011	1.41	0.00*	1.14		1.73		27.17	0.51	0
Ekman et al., 2004	1.38	0.00*	1.13		1.69		27.55	0.49	0
Errando et al., 2008	1.33	0.01*	1.08		1.64		25.11	0.62	0
Goldman et al., 1987	1.41	0.00*	1.15		1.73		23.67	0.70	0
Kerssens et al., 2003	1.38	0.00*	1.12		1.69		27.48	0.49	0
Lallemand et al. (0.2mg/kg), 2003	1.38	0.00*	1.13		1.69		27.56	0.54	0
Lallemand et al. (0.3mg/kg), 2003	1.38	0.00*	1.13		1.69		27.56	0.54	0
Lallemand et al. (0.4mg/kg), 2003	1.38	0.00*	1.13		1.69		27.56	0.54	0
Lennertz et al., 2022	1.39	0.00*	1.14		1.70		27.33	0.50	0
Liu et al., 1999	1.39	0.00*	1.14		1.70		27.21	0.51	0
Messahel et al., 2007	1.38	0.00*	1.13		1.69		27.56	0.54	0
Miller et al. (PLAC), 1996	1.37	0.00*	1.12		1.68		26.87	0.53	0
Miller et al. (M-15), 1996	1.38	0.00*	1.13		1.69		27.33	0.50	0
Miller et al. (M-30), 1996	1.38	0.00*	1.13		1.69		27.56	0.54	0
Miller et al. (M-45), 1996	1.38	0.00*	1.13		1.69		27.34	0.50	0
Myles et al. (BIS), 2004	1.36	0.00*	1.11		1.67		27.18	0.51	0
Myles et al. (RC), 2004	1.38	0.00*	1.12		1.70		27.55	0.49	0
Nordstrom et al., 1997	1.38	0.00*	1.13		1.68		27.09	0.51	0
Sanders et al., 2017	1.38	0.00*	1.13		1.69		27.56	0.54	0
Sandin et al., 2000	1.40	0.00*	1.14		1.71		27.39	0.50	0
Schneider et al. (Sevo, low remi), 2003	1.38	0.00*	1.13		1.69		27.56	0.54	0
Schneider et al. (Sevo, high remi), 2003	1.38	0.00*	1.13		1.69		27.56	0.54	0
Schneider et al. (Prop, low remi), 2003	1.38	0.00*	1.13		1.69		27.56	0.54	0
Schneider et al. (Prop, high remi), 2003	1.38	0.00*	1.13		1.69		27.56	0.54	0
Sebel et al., 2014	1.44	0.00*	1.15		1.79		26.93	0.52	0
Singla et al., 2017	1.39	0.00*	1.13		1.70		27.53	0.49	0
Wang et al., 2011	1.38	0.00*	1.13		1.70		27.56	0.49	0
Wennervirta et al., 2002	1.35	0.00*	1.11		1.66		25.63	0.59	0
Wilson et al., 1975	1.37	0.00*	1.12		1.67		26.18	0.56	0
Xu et al., 2009	1.34	0.01*	1.09		1.67		27.00	0.52	0
Yu et al., 2017	1.39	0.00*	1.13		1.70		27.54	0.49	0
Zhang et al. (BIS), 2011	1.38	0.00*	1.13		1.68		27.40	0.50	0

Zhang et al. (RC), 2011	1.41	0.00*	1.15	1.73	26.64	0.54	0
Celebioglu et al., 2022	1.37	0.00*	1.12	1.67	26.65	0.54	0
Heggy et al., 2020	1.39	0.00*	1.14	1.70	26.42	0.55	0
Hou et al., 2019	1.45	0.00*	1.18	1.79	23.89	0.69	0
Li et al., 2021	1.38	0.00*	1.13	1.69	27.56	0.54	0
Ranta et al., 1998	1.36	0.00*	1.11	1.67	27.01	0.52	0
Stait et al., 2008	1.35	0.00*	1.10	1.65	24.23	0.67	0

* p < 0.05

Abbreviations: BIS, Bispectral index; CI, confidence interval; ETAG, end-tidal anaesthetic gas; E-0.2, etomidate 0.2 mg/kg; E-0.3, etomidate 0.3 mg/kg; E-0.4, etomidate 0.4 mg/kg; M-15, midazolam 15 mcg/kg; M-30, midazolam 30 mcg/kg; M-45, midazolam 45 mcg/kg; PLAC, placebo; Prop, propofol; remi, remifentanyl; Sevo, sevoflurane; SP, standard practice.

Supplementary table 8. Studies reporting data on emergence from anesthesia

Anesthetic parameter	Studies (n)	Population (n)			Measure	Outcome ^a	
		Female	Male	Total			
Eye opening	10	1959	2507	4466	Time (minutes)	Range across studies	2.9 – 15.5
						Females	15.5 – 25.3
						Males	3.9 – 25.3
Response to/obeying verbal command	7	769	696	1456	Time (minutes)	Range across studies	5.6 – 12.4
						Females	8.3 – 19.0
						Males	8.3 – 19.0
Extubation	5	1544	1975	3519	Time (minutes)	Range across studies ^b	3.2 – 10.6
						Females	3.5 – 12.2
						Males	3.5 – 12.2
Duration of PACU stay	3	1396	2030	3426	Time (minutes)	Range across studies	38.8 – 67.4
						Females	33.7 – 64.0
						Males	33.7 – 64.0
Orientation	4	275	271	546	Time (minutes)	Range across studies	9.1 – 17.5
						Females	9.3 – 16
						Males	9.3 – 16
OAA/S score >5	1	16	16	32	Time (minutes)	Females	9.5 – 14.5
						Males	9.3 – 9.5
Other							
% 'awake' by 30 minutes	1	46	61	107	% patients	Female	83%
						Male	57%
Awakening concentration (%) of volatile	1	20	19	39	% volatile	No significant difference	

^aFurther specifications of outcomes for each study are available in supplementary material


^bExcluding study that reported time to extubation for patients admitted to ICU³⁴

Abbreviations: OAA/S: observer's assessment of alertness and sedation.


Supplementary table 9. Sequential exclusion analysis for time to eye opening emergence data.

Author, year	Effect size				Heterogeneity				
	Mean difference (min) ¹	p-value	95% lower bound	CI upper bound	95% CI	Cochran's Q	p-value	Tau ²	I ² (%)
Buchanan et al. (b), 2011	-2.08	0.00 ^t	-3.39	-0.77		135.88	0	3.44	90.76
Buchanan et al. (a), 2006	-1.89	0.01 ^t	-3.12	-0.66		158.76	0	2.81	90.58
Gan et al., 2013	-1.90	0.00 ^t	-3.10	-0.69		165.47	0	2.80	90.67
Kreuer et al. (SP), 2003	-2.19	0.00 ^t	-3.47	-0.91		173.88	0	3.35	91.95
Kreuer et al. (BIS), 2003	-2.19	0.00 ^t	-3.48	-0.90		173.39	0	3.40	91.87
Kreuer et al. (Narcotrend), 2003	-2.19	0.00 ^t	-3.49	-0.89		172.24	0	3.43	91.55
Riaphus et al., 2017	-2.26	0.00 ^t	-3.39	-1.14		119.10	0	2.22	84.78
Tercan et al. (Des), 2005	-2.27	0.00 ^t	-3.43	-1.11		137.91	0	2.49	86.19
Tercan et al. (Sevo), 2005	-1.91	0.00 ^t	-3.02	-0.81		167.33	0	2.76	90.64
Ward et al. (IDD-D Propofol), 2002	-1.96	0.00 ^t	-3.13	-0.78		169.92	0	2.90	91.04
Ward et al. (Diprivan), 2002	-2.13	0.00 ^t	-3.44	-0.81		164.28	0	3.48	91.66
Bajaj et al., 2007	-2.10	0.00 ^t	-3.39	-0.80		172.24	0	3.36	92.07
Im et al. (18-29y.o), 2011	-2.11	0.00 ^t	-3.41	-0.82		172.71	0	3.37	92.09
Im et al. (30-39 y.o), 2011	-1.96	0.01 ^t	-3.23	-0.69		160.18	0	3.09	91.28
Im et al. (40-45 y.o), 2011	-1.89	0.00 ^t	-3.06	-0.72		166.61	0	2.73	90.49
Myles et al., 2004	-2.11	0.00 ^t	-3.41	-0.80		168.31	0	3.44	92.00
Myles et al., 2001	-2.15	<0.05	-3.35	-0.94		179.39	0	3.20	91.23


¹Females - Males




Supplementary figure 1. Forest plot of total (possible + confirmed) incidence of awareness with recall. BIS, Bispectral index; ETAG, end-tidal anaesthetic gas; Midaz-15, midazolam 15mcg/kg; Midaz-30, midazolam 30mcg/kg; Midaz-45, midazolam 45 mcg/kg; Prop, propofol; PLAC, placebo; remi, remifentanyl; sevo, sevoflurane; SP, standard practice.




Supplementary figure 2. Summary forest plot of confirmed awareness data for differing methods of analysis. BIS, Bispectral index; ETAG, end-tidal anaesthetic gas; Midaz-15, midazolam 15mcg/kg; Midaz-30, midazolam 30mcg/kg; Midaz-45, midazolam 45 mcg/kg; Prop, propofol; PLAC, placebo; remi, remifentanyl; sevo, sevoflurane; SP, standard practice.




Supplementary figure 3. Summary forest plot of total (confirmed and possible) awareness data for differing methods of analysis. BIS, Bispectral index; ETAG, end-tidal anaesthetic gas; 0.2mg/kg, etomidate 0.2mg/kg; 0.3mg/kg, etomidate 0.3mg/kg; 0.4mg/kg, etomidate 0.4mg/kg; M-15, midazolam 15mcg/kg; M-30, midazolam 30mcg/kg; M-45, midazolam 45 mcg/kg; Prop, propofol; PLAC, placebo; RC, routine care; remi, remifentanyl; sevo, sevoflurane.



Supplementary figure 4. Forest plot of confirmed incidence of awareness with recall with removal of studies of concern from REAPPRAISED assessment. BIS, Bispectral index; ETAG, end-tidal anaesthetic gas; Midaz-15, midazolam 15mcg/kg; Midaz-30, midazolam 30mcg/kg; Midaz-45, midazolam 45 mcg/kg; PLAC, placebo; SP, standard practice.



Supplementary figure 5. Forest plot of emergence times (time to eye opening) in females versus males with exclusion of studies of concern from REAPPRAISED assessment. BIS, Bispectral Index; SP, standard practice.



Supplementary figure 6. Forest plot of emergence times (time to extubation) in females versus males. BIS, bispectral index; Des, desflurane; Sevo, sevoflurane; SP, standard practice.